The Diagnostic Value of Fibrin- and Fibrinogen Degradation Products in Perinatology

  • Reimar Hafter
  • Henner Graeff
Conference paper


Thromboembolic episodes and intravascular coagulation are more frequent during gestation and in certain groups of high-risk patients than in non-pregnant and healthy individuals. Hypercoagulability may be one of the underlying conditions. The so-called state of hypercoagulability is reflected in the levels of thrombin-mediated soluble fibrin monomer complexes (SFMC).


Disseminate Intravascular Coagulation Ascitic Fluid Disseminate Intravascular Coagulation Endotoxin Shock Fibrin Degradation Product 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alkjaersig N, Fletcher AP, Burstein R (1971) Thromboembolism and oral contraceptive medication. Thromb Diathesis Haemorrh (Suppl) 49: 125–129Google Scholar
  2. 2.
    Hafter R, Graeff H (1976) Estimation of soluble fibrin monomer complexes by agarose gel filtration. In: Davidson JF, Samama MM, Desnoyers PC (eds) Progress in chemical fibrinolysis and thrombolysis, vol 2. Raven, New York, pp 137–149Google Scholar
  3. 3.
    Hafter R, Schneebauer T, Tafel K, Ernst E, Graeff H (1975) Bestimmung von löslichen Fibrinmonomerkomplexen zur Erfassung der Hyperkoagulabilität in der Schwangerschaft und unter der Geburt. Geburtsh u Frauenheilk 35: 518–525Google Scholar
  4. 4.
    Graeff H, Von Hugo R, Hafter R (1980) Hypercoagulability and intravascular coagulation in obstetrics and gynaecology. In: Coccheri S (ed) Vth International Congress on Thromboembolism, Bologna May 29-June 2, 1978. Proceedings, Quaderni della Coagulazine, pp 449–451Google Scholar
  5. 5.
    McKillop C, Forbes CD, Howie PW, Prentice CRM (1976) Soluble fibrin monomer complexes in preeclampsia. Lancet I: 56–58CrossRefGoogle Scholar
  6. 6.
    Van Royen EA, Ten Cate JW (1976) Generation of a thrombinlike activity in late pregnancy. Thromb Res 8: 487–492PubMedCrossRefGoogle Scholar
  7. 7.
    Graeff H, Hafter R, Von Hugo R (1976) Hyperkoagulabilität und Thromboseneigung in Schwangerschaft und Wochenbett. In: Ludwig H, Kurz H (eds) Die Beckenvenen. Schattauer, Stuttgart, pp 223–230Google Scholar
  8. 8.
    Graeff H, Wiemann A, Von Hugo R, Hafter R (1976) Amount and distribution pattern of soluble fibrin monomer complexes during the early puerperium. Am J Obstet Gynecol 124: 21–24PubMedGoogle Scholar
  9. 9.
    Graeff H, Hafter R, Bachmann L (1979) Subunit and macromolecular structure of circulating fibrin from obstetric patients with intravascular coagulation. Thromb Res 16: 313–328PubMedCrossRefGoogle Scholar
  10. 10.
    Graeff H, Hafter R (1982) Detection and relevance of crosslinked fibrin derivatives in blood. Semin Thromb Hemost 8: 57–68PubMedCrossRefGoogle Scholar
  11. 11.
    Hafter H, Graeff H (1982) Homologues of fibrin X oligomers. In: Henschen A, Graeff H, Lottspeich F (eds) Fibrinogen—recent biochemical and medical aspects. de Gruyter, Berlin, pp 291–305Google Scholar
  12. 12.
    Francis CW, Marder VJ (1982) A molecular model of plasmic degradation of cross-linked fibrin. Semin Thromb Hemost 8: 25–35PubMedCrossRefGoogle Scholar
  13. 13.
    Marder VJ, Francis CW (1984) Plasmin degradation of cross-linked fibrin. Ann NY Acad Sci 408: 397–406CrossRefGoogle Scholar
  14. 14.
    Gaffiney PJ (1982) Fibrin fragmentation by plasmin: molecular considerations and their relevance to DIC and thrombosis. In: Henschen A, Graeff H, Lottspeich F (eds) Fibrinogen—recent biochemical and medical aspects, de Gruyter, Berlin, pp 307–327Google Scholar
  15. 15.
    Gaffney PJ (1983) The occurrence and clinical relevance of fibrin fragments in blood. Ann NY Acad Sci 408: 407–423PubMedCrossRefGoogle Scholar
  16. 16.
    Graeff H, Hafter R (1987) Clinical aspects of fibrinolysis. In: Bloom AL, Thomas DP (eds) Haemostasis and thrombosis. Churchill Livingstone, Edinburgh, pp 245–254Google Scholar
  17. 17.
    Kopec M, Teisseyre E, Dudek-Wojciechowska G, Kloczewiak M, Pankiewicz A, Latallo CS (1973) Studies on the double D fragment from stabilized bovine fibrin. Thromb Res 2: 283–292CrossRefGoogle Scholar
  18. 18.
    Gaffney PJ, Lane DA, Kakkar VV, Brasher M (1975) Characterization of a soluble D-dimer-E complex in cross-linked fibrin digests. Thromb Res 7: 89–99PubMedCrossRefGoogle Scholar
  19. 19.
    Whitaker AN, Rowe EA, Masci PP, Gaffney PJ (1980) Identification of a D-dimer-E complex in disseminated intravascular coagulation. Thromb Res 19: 381–391PubMedCrossRefGoogle Scholar
  20. 20.
    Hafter R, Klaubert W, Gollwitzer R, Von Hugo R, Graeff H (1984) Cross-linked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis. Thromb Res 35: 53–64PubMedCrossRefGoogle Scholar
  21. 21.
    Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN (1983) Measurement of cross-linked fibrin degradation products—an immunoassay using monoclonal antibodies. Thromb Haemost 50 (2): 591–594PubMedGoogle Scholar
  22. 22.
    Hafter R, Schröck R, Von Hugo R, Graeff H (1985) Measurement of cross-linked fibrin derivatives in plasma and ascitic fluid with monoclonal antibodies against D-dimer using EIA and Latex test. Scand J Clin Lab Invest 45 (Suppl) 178: 137–144Google Scholar
  23. 23.
    Hafter R, Schröck R, Von Hugo R, Graeff H (1986) Clinical aspects of fibrin formation and fibrinolysis measured with monoclonal antibodies against D-dimer. In: Lane DA, Henschen A, Jasani MK (eds) Fibrinogen—fibrin formation and fibrinolysis, de Gruyter, Berlin, pp 303–312Google Scholar
  24. 24.
    Nieuwenhuizen W (1987) Plasma assays of fibrinogen/fibrin degradation products and their clinical relevance. In: Lowe GDO, Douglas JT, Forbes CD, Henschen A (eds) Fibrinogen—biochemistry, physiology and clinical relevance. Elsevier, Amsterdam, pp 173–180Google Scholar
  25. 25.
    Scheefers-Borchel U, Müller-Berghaus G, Fuhge P, Eberle R, Heimburger N (1985) Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide. Proc Natl Acad Sci USA 82: 7091–7095PubMedCrossRefGoogle Scholar
  26. 26.
    Koppert PW, Kuipers W, Hoegee-de Nobel, Brommer EJP, Koopman J, Nieuwenhuizen W (1987) A quantitative enzyme immunoassay for primary fibri-nogenolysis products in plasma. Thromb Haemost 57 (1): 25–28PubMedGoogle Scholar

Copyright information

© Springer Japan 1991

Authors and Affiliations

  • Reimar Hafter
    • 1
  • Henner Graeff
    • 1
  1. 1.Frauenklinik der Technischen Universität MünchenMünchen 80Federal Republic of Germany

Personalised recommendations